# InterVene, Inc.

> InterVene, Inc. is a Redwood City, California vascular medical device company building catheter-based tools for severe venous disease. Born out of Stanford Biodesign, it first pioneered BlueLeaf, a non-implantable system that forms new vein valves from a patient's own tissue, then pivoted its lead product to Recana, an FDA-cleared thrombectomy catheter system that clears venous in-stent restenosis and native-vessel obstructions - a stubborn problem that leaves stented patients with debilitating complications and few good options.

- **Founded:** 2011
- **Headquarters:** Redwood City, California, United States
- **Founders:** Fletcher Wilson (Founder (former CEO))
- **Team size:** ~18 employees
- **Products:** Recana Thrombectomy Catheter System, BlueLeaf Endovenous Valve Formation (EVF) System, Stratus Venous Infusion Catheter
- **Notable:** FDA 510(k) clearance for the Recana Thrombectomy Catheter System (October 2025), First fully integrated system for venous in-stent restenosis and native-vessel obstructions, FDA Breakthrough Device Designation for BlueLeaf (December 2021)

## Products & services

- **Recana Thrombectomy Catheter System** — An FDA-cleared, fully integrated system - the first designed specifically for venous in-stent restenosis and native-vessel obstructions. It pairs a stainless-steel helical debulking catheter (with a sharpened, beveled coring element and spiral nose cone for crossing occlusions) with nitinol material-collection baskets and introducer/collection sheaths. It requires no capital equipment and uses standard fluoroscopy and IVUS-guided technique.
- **BlueLeaf Endovenous Valve Formation (EVF) System** — A non-implantable, catheter-based system that uses hydrodissection to form new functional valves from a patient's own vein-wall tissue to treat deep-vein reflux and chronic venous insufficiency. Granted FDA Breakthrough Device Designation in 2021; the lead focus later shifted to Recana.
- **Stratus Venous Infusion Catheter** — An earlier, enabling venous catheter product tied to the company's hydrodissection and venous-access technology. Minimal public footprint; treated as a legacy or ancillary product.

## Achievements

- FDA 510(k) clearance for the Recana Thrombectomy Catheter System (October 2025)
- First fully integrated system for venous in-stent restenosis and native-vessel obstructions
- FDA Breakthrough Device Designation for BlueLeaf (December 2021)
- Early BlueLeaf data: ~93% of patients formed at least one valve; ~97% of valves patent at one year
- First-in-human Recana procedure completed (July 2025)
- 30 Recana cases completed by April 2026, with broader commercial launch planned for 2026
- Raised ~$34-38M cumulatively across seed, Series B, and a recapitalized Series A

## Latest updates

- **2026-04** — Completed first 30 cases with the Recana Thrombectomy Catheter System; broader US commercial launch planned for later in 2026.
- **2025-10** — Received FDA 510(k) clearance for the Recana Thrombectomy Catheter System.
- **2025-07** — Completed first-in-human Recana procedure treating venous in-stent restenosis.
- **2024-10** — Closed a $13M recapitalized Series A financing co-led by Treo Ventures and RiverVest Venture Partners.

## Links

- Website: https://intervene-med.com
- LinkedIn: https://www.linkedin.com/company/intervene-med

---

Profile page: https://yespress.io/intervene-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-11